{'fraction_non_alphanumeric': 0.018970189701897018, 'fraction_numerical': 0.0040650406504065045, 'mean_word_length': 5.598214285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diagnostic and Treatment Dilemmas in Pediatric NAFLD

Based on expert opinion, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) recommends screening for NAFLD between 9 and 11 years of age with alanine aminotransferase (ALT) levels in obese children or in overweight children with additional risk factors. This differs from the American Association for the Study of Liver Diseases Practice Guidance, which does not recommend screening in children because of a paucity of data. In contrast, there are no recent screening guidelines from the American Academy of Pediatrics. In short, consistent guidelines and additional data are needed to improve NAFLD screening and diagnosis among children.